Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Lausanne's university hospital and Ludwig branch, home of the temozolomide glioblastoma trial, Solange Peters and a leading personalised T-cell therapy programme.
The CHUV Department of Oncology, headed by Solange Peters (ESMO president 2020-2021), works with the Ludwig Institute for Cancer Research Lausanne branch under George Coukos, the University of Lausanne, EPFL's ISREC institute and the Geneva hospitals within the Swiss Cancer Center Léman, housed in the AGORA research building opened in 2018. Roger Stupp led from Lausanne the EORTC/NCIC trial that made radiotherapy plus temozolomide the standard for glioblastoma, and Douglas Hanahan, author of 'The Hallmarks of Cancer', directed ISREC. The Ludwig groups run personalised tumour-infiltrating lymphocyte and neoantigen-targeted T-cell trials in ovarian and other cancers, and the hospital is a major thoracic oncology and immunotherapy trial site with a phase 1 unit.
- Ludwig Lausanne immuno-oncology
- Personalised TIL and T-cell therapy
- Thoracic oncology
- Neuro-oncology heritage
- Swiss Cancer Center Léman
Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.
Led the EORTC/NCIC trial that made temozolomide with radiotherapy the glioblastoma standard, and the EF-14 trial of tumour treating fields.